Loading stock data…
Capricor Therapeutics, Inc. (CAPR)
$9.06-0.34 (-3.62%)
Market ClosedLast close Sep 8
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Capricor Therapeutics, Inc. in the Healthcare sector is trading at $9.06 with a market capitalization of $1.6B. Wall Street consensus targets $28.50 (4 analysts), implying a +214.6% move over the next 12 months. The stock is currently near its 52-week low of $2.96, remaining 61.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +214.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$36.77M↓ | -$29.16M↓ | -$26.28M↑ | -$27.72M↓ | -$24.98M |
| Net Income | -$33.94M↓ | -$30.17M↓ | -$24.57M↑ | -$25.91M↓ | -$24.39M |
Peer Comparison
JNJUNHPFE
Fundamentals
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the Un...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-41.12%
Volume
Today's trading volume
2.72M
Recent News
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.
Could New Long-Term Data Support Capricor’s Duchenne Therapy?
Capricor Therapeutics, Inc. (NASDAQ:CAPR) has gained another opportunity to make the case for deramiocel, its experimental cell therapy for Duchenne muscular dystrophy. The FDA extended its review by three months after accepting new 24-month clinical data and additional analyses from the company. The submission supports a refined proposed indication focused on upper limb function, which […]
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index adding 0.6% and
Capricor Therapeutics shares rise 2.5% following August FDA update
Capricor Therapeutics (NASDAQ:CAPR) shares rose 2. 5% in pre-market trading to $10.
Why Is CAPR Stock Rising Today? Piper Sandler Says Risk-Reward Favors Owning Stock Into FDA Decision
Piper Sandler upgraded Capricor to ‘Overweight’ from ‘Neutral’ and sharply raised the price target to $25, a roughly 150% upside potential from current levels.